Medicare Savings from Alzheimer's Lecanemab
This is a US news story, published by ScienceDaily, that relates primarily to Chi-Hong Tseng news.
US news
For more US news, you can click here:
more US newsChi-Hong Tseng news
For more Chi-Hong Tseng news, you can click here:
more Chi-Hong Tseng newsdrug discoveries news
For more drug discoveries news, you can click here:
more drug discoveries newsScienceDaily news
For more news from ScienceDaily, you can click here:
more news from ScienceDailyAbout the Otherweb
Otherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
Medicare budget. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest unused medication news, Medicare hundreds news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
expensive medicationScienceDaily
•Smaller vial size for Alzheimer's drug could save Medicare hundreds of millions per year
77% Informative
Nearly 6% of Alzheimer's drug lecanemab is discarded, costing Medicare $ 1,600 per patient per year.
The researchers on the study estimate that Medicare could waste up to $336 million annually due to discarded medication.
Administered dosages are based on each patient's body weight.
Journal Reference: - Frank F. Zhou, Chi-Hong Tseng , Mei Leng , Benjo A. Delarmente , Cheryl L. Damberg , Catherine A. Sarkisian , John N. Mafi . Reducing Wasteful Spending on Discarded Lecanemab in the US Medicare Program. JAMA Internal Medicine , 2024 ; DOI: 10.1001 /jamainternmed.2024.5292 Cite This Page:.
VR Score
89
Informative language
98
Neutral language
27
Article tone
formal
Language
English
Language complexity
60
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
medium-lived
External references
no external sources
Source diversity
no sources
Affiliate links
no affiliate links